scholarly journals Cryptococcosis in non-HIV/non-transplant patients: A Brazilian case series

2016 ◽  
Vol 54 (7) ◽  
pp. 669-676 ◽  
Author(s):  
Naiane Ribeiro Lomes ◽  
Marcia Souza de Carvalho Melhem ◽  
Maria Walderez Szeszs ◽  
Marilena dos Anjos Martins ◽  
Renata Buccheri
Keyword(s):  
Case Series ◽  
Transplant Patients ◽  
Brazilian Case

scholarly journals 530. COVID-19 in kidney transplant recipients: Single-center experience and case-control study

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S332-S332
Author(s):  
Anna Hardesty ◽  
Aakriti Pandita ◽  
Yiyun Shi ◽  
Kendra Vieira ◽  
Ralph Rogers ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Case Control Study ◽  
Clinical Course ◽  
Case Series ◽  
Case Fatality ◽  
Case Control ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Transplant Patients ◽  
Control Study

Abstract Background Organ transplant recipients (OTR) are considered high-risk for morbidity and mortality from COVID-19. Case-fatality rates (CFR) vary significantly in different case series, and some patients were still hospitalized at the time of analyses. To our knowledge, no case-control study of COVID-19 in OTR has been published to-date. Methods We captured kidney transplant recipients (KTR) diagnosed with COVID-19 between 3/1 and 5/18/2020. After exclusion of KTR on hemodialysis and off immunosuppression (IS), we compared the clinical course of COVID-19 between hospitalized KTR and non-transplant patients, matched by sex and age (controls). All patients were discharged from the hospital or died. Results 16 KTR had COVID-19. All 3 KTR off IS, who were excluded from further analyses, survived. Median age was 54 (range: 34–65) years; 5/13 KTR (38.4%) were men. Median time from transplant was 41 (range: 1–203) months. Two KTR, both transplanted >10 years ago, were managed as outpatients. IS was reduced in 12/13 (92.3%), most often by discontinuation of the antimetabolite. IL6 levels were >1,000 (normal: < 5) pg/mL in 3 KTR. Tacrolimus or sirolimus levels were >10 ng/mL in 6/9 KTR (67%) (Table 1). Eleven KTR were hospitalized (84.6%) and matched with 44 controls. One KTR, the only one treated with hydroxychloroquine, died (CFR 5.8%; 7.6% in KTR on IS; 9% in hospitalized KTR on IS). Four controls died (CFR: 9%; state CFR: 5.2%; inpatient CFR: 16.6%). There were no significant differences in length of stay or worst oxygenation status between hospitalized KTR and controls. Four KTR (30.7%), received remdesivir, 4 convalescent plasma, 3 (23%) tocilizumab. KTR received more often broad-spectrum antibiotics, convalescent plasma or tocilizumab, compared to controls (Table 2). Table 1 Table 2 Conclusion Unlike early reports from the pandemic epicenters, the clinical course and outcomes of KTR with COVID-19 in our small case series were comparable to those of non-transplant patients. Calcineurin or mTOR inhibitor levels were high, likely due to diarrhea and COVID-19-related hepatic dysfunction. Extremely high IL6 levels were common. The role of IS and potential benefits from investigational treatments remain to be elucidated. A larger multi-institutional study is underway. Disclosures All Authors: No reported disclosures

Sinonasal Posttransplant Lymphoproliferative Disorder in Pediatric Lung Transplant Patients

2005 ◽  
Vol 133 (1) ◽  
pp. 38-41 ◽  
Author(s):  
Brian W. Herrmann ◽  
Stuart C. Sweet ◽  
David W. Molter
Keyword(s):  
Cystic Fibrosis ◽  
Head And Neck ◽  
Lymphoproliferative Disorder ◽  
Lung Transplant ◽  
Nasal Polyposis ◽  
Case Series ◽  
Posttransplant Lymphoproliferative Disorder ◽  
Transplant Patients ◽  
Occult Disease ◽  
Lung Transplants

OBJECTIVE: To evaluate sinonasal manifestations of posttransplant lymphoproliferative disorder (PTLD) in the pediatric lung transplant population. STUDY DESIGN AND METHODS: Case series of children less than 18 years presenting with PTLD after pulmonary transplantation at St Louis Children's Hospital between Jan 1, 1990 and Dec 31, 2003. RESULTS: Two hundred eighty-two lung transplants were performed in 246 children. Thirty-two cases of histopathologically confirmed PTLD were identified with 8 (25%) presenting in the head and neck. Sinonasal PTLD was the most common site of head and neck involvement (63%), with 40% of patients presenting with occult disease. All patients with sinonasal PTLD had longstanding nasal polyposis related to cystic fibrosis ( P = 0.07). CONCLUSIONS: This is, to our knowledge, the first report identifying an increased frequency of sinonasal PTLD after pediatric pulmonary transplantation, particularly in children with cystic fibrosis and associated nasal polyposis. Because sinonasal PTLD may be asymptomatic, this region should receive close scrutiny on surveillance evaluations.

Insights From Practice With Use of Direct Oral Anticoagulants in Transplantation

2018 ◽  
Vol 28 (4) ◽  
pp. 380-385
Author(s):  
Razan Alsheikh ◽  
Osamah M. Alfayez ◽  
Majed S. Al Yami
Keyword(s):  
Case Reports ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Organ Transplant ◽  
Case Series ◽  
Solid Organ ◽  
Special Population ◽  
Retrospective Case ◽  
Transplant Patients ◽  
Attractive Option

Solid organ transplant patients are at risk of developing atrial fibrillation and venous thromboembolism. Direct oral anticoagulants are considered an attractive option for anticoagulation in patients due to their convenience; however, strong evidence of their use in transplantation is lacking. We conducted a search using Pubmed, Embase, and Scopus databases, in addition to International Society of Heart and Lung transplantation and American Transplant Congress abstracts (from 2012 through December 2017). Fourteen articles were reviewed that included case reports, retrospective case series, or chart review analyses of small cohorts. Based on this review, the findings can only generate hypotheses that should be further studied in a larger randomized cohort. This review can help clinicians gain insight into the use of direct oral anticoagulant in this special population. For now, clinicians should be cautious about their use in this special population.

Combined Therapy With Surgery and Anti-TNF Therapy for Perianal Crohnʼs Disease: Seton Withdrawal Timing Data From a Brazilian Case Series

2012 ◽  
Vol 18 ◽  
pp. S59
Author(s):  
Paulo Kotze ◽  
Idblan Albuquerque ◽  
Andre Moreira ◽  
Claudio Coy ◽  
Ana Pugas de Carvalho ◽  
...  
Keyword(s):  
Combined Therapy ◽  
Case Series ◽  
Timing Data ◽  
Brazilian Case

The use of drotrecogin alfa (activated) in solid organ transplant patients: a case series

2009 ◽  
Vol 11 (3) ◽  
pp. 269-276
Author(s):  
S. Berkman ◽  
N.A. Weimert ◽  
D.J. Taber ◽  
G.M. Baillie ◽  
A. Lin ◽  
...  
Keyword(s):  
Drotrecogin Alfa ◽  
Organ Transplant ◽  
Case Series ◽  
Solid Organ Transplant ◽  
Solid Organ ◽  
Transplant Patients ◽  
Drotrecogin Alfa Activated

scholarly journals Severe cutaneous adverse drug reactions: diagnostic approach and genetic study in a Brazilian case series

2021 ◽  
Author(s):  
M. I. Perello ◽  
A. de Maria Castro ◽  
A. C. Nogueira Arraes ◽  
S. Caracciolo Costa ◽  
D. Lacerda Pedrazzi ◽  
...  
Keyword(s):  
Adverse Drug Reactions ◽  
Genetic Study ◽  
Case Series ◽  
Diagnostic Approach ◽  
Drug Reactions ◽  
Brazilian Case

scholarly journals Resolution of cryptosporidiosis in transplant recipients: review of the literature and presentation of a renal transplant patient treated with nitazoxanide, azithromycin, and rifaximin

2021 ◽  
Author(s):  
Ewa Tomczak ◽  
April N McDougal ◽  
A Clinton White
Keyword(s):  
Renal Transplant ◽  
Renal Transplant Patient ◽  
Transplant Patient ◽  
Diarrheal Disease ◽  
Case Series ◽  
Combination Therapies ◽  
Middle Income ◽  
Transplant Patients ◽  
Current Therapies ◽  
Cellular Immune

Abstract Cryptosporidium is a major cause of diarrheal disease worldwide, including chronic disease in malnourished children and patients with AIDS. There are increasing reports of cryptosporidiosis in transplant patients, especially from middle-income countries. The literature on treatment of cryptosporidiosis in transplant patients was reviewed and included no controlled trials, but only small case series. Nitazoxanide, azithromycin, spiramycin, and combination therapies have been used, but none are consistently efficacious. We present a case of chronic diarrhea from cryptosporidiosis in a renal transplant patient. His illness resolved with decreasing immunosuppression and treatment with the 3-drug combination of nitazoxanide, azithromycin, and rifaximin. While current therapies are not reliably effective in the absence of an effective cellular immune response, combination therapies hold promise for improved responses.

Sign in / Sign up

Export Citation Format

Share Document